THE VILLAGES, Fla. , Oct. 25, 2024 /PRNewswire/ — K2 Medical Research celebrates an important milestone in the fight against Alzheimer’s disease: successfully randomizing the world’s first patients in the J&J ReTain study We are proud to announce that. This landmark clinical trial aims to evaluate the effects of an investigational drug on cognitive decline in preclinical Alzheimer’s disease (AD).
The ReTain trial aims to investigate how this new treatment affects not only cognitive function, but also the accumulation of tau protein in the brain, an important marker associated with the progression of Alzheimer’s disease. I’m here. Researchers will utilize advanced tau PET imaging to collect important data about how the investigational drug may alter the trajectory of cognitive decline and tau accumulation in participants.
Dr. Craig Curtis, principal investigator at K2 Medical Research, said: “By becoming the first site to randomize patients in the ReTain study, we have taken an important step toward understanding and potentially mitigating the impact of Alzheimer’s disease.”
The ReTain study is part of a larger effort to develop effective treatments for individuals at risk of developing symptoms of Alzheimer’s disease. As the world’s population continues to age, the need for innovative research in this field has never been greater. The results of this study could pave the way for new treatment strategies that have the potential to improve the quality of life for the millions of people who suffer from this debilitating disease.
K2 Medical Research is committed to advancing medical knowledge and improving patient outcomes through rigorous clinical trials and innovative research methodologies.
For more information about the J&J ReTain study or how to participate, please visit our website at www.k2med.com or contact our research team directly.
About K2 Medical Research
K2 Medical Research is a leading clinical research organization based in The Villages, Central Florida, and Tampa, Florida, dedicated to conducting high-quality research in neurology and other medical specialties. Our mission is to bring new treatments to patients through innovative research and collaborative partnerships.
contact:
Sandra Carmona Torres
Executive Director, Patient Engagement, Marketing and Diversity
K2 Medical Research
Phone: 407-818-1957
Email: Sandra.torres@k2med.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/k2-medical-research-the-villages-achieves-landmark-milestone-in-alzheimers- research-302287541.html
Source K2 Medical Research
